Oct 24 (Reuters) - Biogen (BIIB.O), opens new tab said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to expand its pipeline of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results